Thursday, December 21, 2006

Medicine: J&J wins FDA approval for Risperdal 2.0 (Haldol 3.0)

The new treatment is designed to deliver paliperidone -- the active ingredient in Risperdal -- through a technology that allows the drug to remain in the body over a longer period of time.
I'd hate for somebody to have to come up with, ya know, a new drug. Not to say that a longer acting atypical isn't a nice addition to the palette, but the fact that J&J's stock is suddenly worth more because their chemists did some reformulation work on the weekend is pretty frustrating.

No comments: